Emergent BioSolutions Inc. has secured a $51.9 million contract modification to supply CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response $(ASPR)$, a branch of the U.S. Department of Health and Human Services. This modification is part of an existing 10-year contract aimed at enhancing the U.S. smallpox preparedness strategy. Paul Williams, senior vice president at Emergent, emphasized the company's commitment to protecting public health by providing essential medical countermeasures. This contract follows a recent amendment for the company's Botulism Antitoxin Heptavalent (BAT®) with ASPR.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.